Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

Previous smaller but positive studies by Professor Newsome, published in The Lancet and NEJM, had shown that using semaglutide as a treatment for MASH would have benefit for these patients.

Patients with metabolic dysfunction–associated steatohepatitis (MASH) saw reductions in liver fibrosis and steatohepatitis after 72 weeks of treatment with semaglutide (Ozempic, Wegovy; Novo ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH).In this ongoing phase 3, multicenter ...

The diabetes and weight loss drug semaglutide may also reverse signs of liver disease. That’s the headline result of a new clinical trial that tested the popular medication in patients with MASH ...

Using semaglutide injections, ... MASH is a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD), which was previously known as non-alcoholic fatty liver disease, ...

How Can Wegovy Help? How does Wegovy (or any form of 2.4 mg dose of semaglutide) help with MASH?That's exactly what this trial set to find out. Researchers conducted a randomized, double-blind ...